Page 2,862«..1020..2,8612,8622,8632,864..2,8702,880..»

Sold on stem cells

Posted: February 16, 2012 at 7:02 am

Select a Publication:   N E W S P A P E R S ---------------------------------------------- ---Alberta--- Airdrie - Airdrie Echo Banff - Banff Crag and Canyon Beaumont - Beaumont News Calgary - The Calgary Sun Camrose - Camrose Canadian Canmore - Canmore Leader Central Alberta - County Market Cochrane - Cochrane Times Cold Lake - Cold Lake Sun Crowsnest Pass - Crowsnest Pass Promoter Devon - Dispatch News Drayton - Drayton Valley Western Review Edmonton - Edmonton Examiner Edmonton - The Edmonton Sun Edson - Edson Leader Fairview - Fairview Post Fort McMurray - Fort McMurray Today Fort Saskatchewan - Fort Saskatchewan Record Grande Prairie - Daily Herald Tribune Hanna - Hanna Herald High River - High River Times Hinton - Hinton Parklander Lacombe - Lacombe Globe Leduc - Leduc Representative Lloydminster - Meridian Booster Mayerthorpe - Mayerthorpe Freelancer Nanton - Nanton News Peace Country - Peace Country Sun Peace River - Peace River Record Gazette Pincher Creek - Pincher Creek Echo Sherwood Park - Sherwood Park News Spruce Grove - Spruce Grove Examiner Stony Plain - Stony Plain Reporter Strathmore - Strathmore Standard Vermilion - Vermilion Standard Vulcan - Vulcan Advocate Wetaskiwin - Wetaskiwin Times Whitecourt - Whitecourt Star   ---Manitoba--- Altona - Alton Red River Valley Echo Beausejour - Beausejour Review Carman - Carman Valley Leader Gimli - Interlake Spectator Lac Du Bonnet - Lac Du Bonnet Leader Morden - Morden Times Portage la Prairie - Portage Daily Graphic Selkirk - Selkirk Journal Stonewall - Stonewall Argus and Teulon Times Winkler - Winkler Times Winnipeg - The Winnipeg Sun   ---Ontario--- Amherstburg - Amherstburg Echo Bancroft - Bancroft this Week Barrie - Barrie Examiner Barry's Bay - Barry's Bay this Week Belleville - Intelligencer Bradford - Bradford Times Brantford - Expositor Brockville - The Recorder & Times Chatham - Chatham Daily News Chatham - Chatham This Week Chatham - Today's Farmer Clinton - Clinton News-Record Cobourg - Northumberland Today Cochrane - Cochrane Times Post Collingwood - Enterprise Bulletin Cornwall - Standard Freeholder Delhi - Delhi News-Record Dresden - Leader Spirit Dunnville - Dunnville Chronicle Elliot Lake - Standard Espanola - Mid-North Monitor Fort Erie - Times Gananoque - Gananoque Reporter Goderich - Goderich Signal-Star Grand Bend - Lakeshore Advance Haliburton - Haliburton Echo Hanover - The Post Ingersoll - Ingersoll Times Innisfil - Innisfil Examiner Kapuskasing - Kapuskasing Northern Times Kenora - Kenora Daily Miner and News Kenora - Lake of the Woods Enterprise Kincardine - Kincardine News Kingston - Frontenac This Week Kingston - Kingston This Week Kingston - Kingston Whig Standard Kirkland Lake - Northern News Leamington - Leamington Post Lindsay - The Lindsay Post London - The London Free Press London - The Londoner Lucknow - Lucknow Sentinel Midland - Free Press Minden - Minden Times Mitchell - Mitchell Advocate Napanee - Napanee Guide Niagara-on-the-Lake - Niagara Advance Niagara Falls - Review Niagara Falls - Niagara Shopping News Niagara Falls - W. Niagara Community Newspapers North Bay - North Bay Nugget Northumberland - Northumberland Today Norwich - Norwich Gazette Orillia - Packet and Times Ottawa - The Ottawa Sun Owen Sound - Sun Times Oxford - Oxford Review Paris - Paris Star Online Pelham - Pelham News Pembroke - Daily Observer Peterborough - Peterborough Examiner Petrolia - Petrolia Topic Picton - County Weekly News Port Colborne - Inport News Port Hope - Northumberland Today Port Elgin - Shoreline Beacon Sarnia - Observer Sarnia - Sarnia This Week Sault Ste Marie - Sault Star Sault Ste Marie - Sault This Week Seaforth - Seaforth Huron Expositor Simcoe - Simcoe Reformer St. Catharines - St. Catharines Shopping News St. Catharines - Standard St. Thomas - St. Thomas Times-Journal Stirling - Community Press Stratford - The Beacon Herald Strathroy - Strathroy Age Dispatch Sudbury - Sudbury Star Thorold - Thorold News Tillsonburg - Tillsonburg News Timmins - Daily Press Timmins - Timmins Times Toronto - The Toronto Sun Trenton - Trentonian Wallaceburg - Wallaceburg Courier Press Welland - Tribune Welland - Welland News West Lorne - The Chronicle Wiarton - Wiarton Echo Woodstock - Sentinel Review   ---Saskatchewan--- Meadow Lake - Meadow Lake Progress Melfort - Melfort Journal Nipawin - Nipawin Journal   MAGAZINES & SPECIALTY PUBLICATIONS --------- Biz Magazine Business London Cottage Home and Property Showcase Food and Wine Show Georgian Web Hamilton Halton Weddings Hamilton Magazine InterVin International Wine Awards Kingston Life London Citylife Muskoka Magazine Muskoka Trails Niagara Food and Wine Expo Niagara Magazine Ontario Farmer Ontario Golf Sault Bride Guide Sault Dining Sault Good Life Simcoe Life Sudbury Bride Guide The Home Show Vines Magazine What's Up Muskoka

Original post:
Sold on stem cells

Posted in Stem Cells | Comments Off on Sold on stem cells

Research and Markets: Primary and Stem Cells: Gene Transfer Technologies and Applications

Posted: February 16, 2012 at 4:24 am

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/fc9dd6/primary_and_stem_c) has announced the addition of John Wiley and Sons Ltd's new book "Primary and Stem Cells: Gene Transfer Technologies and Applications" to their offering.

This book describes basic cell engineering methods, emphasizing stem cell applications, and use of the genetically modified stem cells in cell therapy and drug discovery. Together, the chapters introduce and offer insights on new techniques for engineering of stem cells and the delivery of transgenes into stem cells via various viral and non-viral systems. The book offers a guide to the types of manipulations currently available to create genetically engineered stem cells that suit any investigator's purpose, whether it's basic science investigation, creation of disease models and screens, or cells for therapeutic applications.

Key Topics Covered:

PART I: CLONING AND GENE DELIVERY

1. DNA Assembly Technologies Based on Homologous Recombination

2. Multigene Assembly for Construction of Synthetic Operons: Creation and Delivery of an Optimized All-IN-One Expression Construct for Generating Mouse iPS Cells

3. Strategies for the Delivery of Naked DNA

PART II: NONINTEGRATING TECHNOLOGIES

4. Episomal Vectors

5. Nonintegrating DNA Virus

6. Nonintegrating RNA Viruses

7. Protein Delivery

PART III: INTEGRATING TECHNOLOGIES

8. Sleeping Beauty Transposon-Mediated Stable Gene Delivery

9. Integrating Viral Vectors for Gene Modifications

10. Bacteriophage Integrases for Site-Specific Integration

11. Improving Gene Targeting Efficiency in Human Pluripotent Stem Cells

PART IV: APPLICATIONS

12. Modified Stem Cells as Disease Models and in Toxicology Screening

13. Screening and Drug Discovery

INDEX

Author:

UMA LAKSHMIPATHY is a principal investigator at Life Technologies. She has a PhD in life sciences, with academic and industry experience in molecular biology and stem cells. Dr. Lakshmipathy holds four patents and has authored more than forty publications.

BHASKAR THYAGARAJAN is a program manager at Life Technologies. He has a PhD in pharmacology, with expertise in the areas of molecular biology, DNA recombination, gene and cell therapy, and protein purification. He holds one patent and has authored more than twenty publications.

For more information visit http://www.researchandmarkets.com/research/fc9dd6/primary_and_stem_c

See the original post here:
Research and Markets: Primary and Stem Cells: Gene Transfer Technologies and Applications

Posted in Stem Cells | Comments Off on Research and Markets: Primary and Stem Cells: Gene Transfer Technologies and Applications

Hot nanotubes blast chemo-resistant breast cancer cells into oblivion

Posted: February 16, 2012 at 4:24 am

These cancer stem cells are difficult to kill because they don't divide rapidly--a common behavior that most cancer treatments target.

When it comes to cancer cells, a particularly confounding breed called cancer stem cells have proven difficult to kill. Because they divide so slowly, chemo drugs do them little harm, and they appear resistant to heat therapies that are generally good at killing most cells. Some cancer drugs even appear to promote the growth of cancer stem cells.

Suzy V. Torti

(Credit: Wake Forest Baptist Medical Center)

Now, three years after they found that the heat from 30-second laser blasts can kill kidney cancer stem cells, researchers at Wake Forest Baptist Medical Center say the same treatment works to kill breast cancer stem cells as well.

Torti's team tested this photothermal therapy on mice, injecting tumors containing breast cancer stem cells with nanotubes that in and of themselves have no anti-tumor properties. When exposed to 30 seconds of laser light from outside the body, however, those nanotubes vibrated and produced sufficient heat to stop the growth of the entire tumor bulk, including the cancer stem cells.

"[Cancer stem cells] are tough," says lead investigator and biochemistry professor Suzy V. Torti. "The advantage of the nanotube approach is that in addition to eliminating the tumor bulk, it would get rid of the stem cells, so presumably these tumors would be less likely to recur than tumors that were treated with something else, like drugs or radiation."

Torti says that while this study only validates this new type of therapy on breast cancer specifically, it may work on other types of cancer stem cells as well. Many questions about how the heat kills the cells remain, however, and she says it will probably take a good five to 10 years of further study before they can investigate the therapy in human clinical trials.

For now, Torti says that the early success of this approach, detailed in the April 2012 issue of the journal Biomaterials, "gives us a direction to go for a cure." Maybe some day it could serve as a non-invasive alternative to surgically removing certain types of malignant tumors.

Visit link:
Hot nanotubes blast chemo-resistant breast cancer cells into oblivion

Posted in Stem Cells | Comments Off on Hot nanotubes blast chemo-resistant breast cancer cells into oblivion

Hot nanotubes blast chemo-resistant cancer cells into oblivion

Posted: February 16, 2012 at 4:24 am

These cancer stem cells are difficult to kill because they don't divide rapidly--a common behavior that most cancer treatments target.

When it comes to cancer cells, a particularly confounding breed called cancer stem cells have proven difficult to kill. Because they divide so slowly, chemo drugs do them little harm, and they appear resistant to heat therapies that are generally good at killing most cells. Some cancer drugs even appear to promote the growth of cancer stem cells.

Suzy V. Torti

(Credit: Wake Forest Baptist Medical Center)

Now, three years after they found that the heat from 30-second laser blasts can kill kidney cancer stem cells, researchers at Wake Forest Baptist Medical Center say the same treatment works to kill breast cancer stem cells as well.

Torti's team tested this photothermal therapy on mice, injecting tumors containing breast cancer stem cells with nanotubes that in and of themselves have no anti-tumor properties. When exposed to 30 seconds of laser light from outside the body, however, those nanotubes vibrated and produced sufficient heat to stop the growth of the entire tumor bulk, including the cancer stem cells.

"[Cancer stem cells] are tough," says lead investigator and biochemistry professor Suzy V. Torti. "The advantage of the nanotube approach is that in addition to eliminating the tumor bulk, it would get rid of the stem cells, so presumably these tumors would be less likely to recur than tumors that were treated with something else, like drugs or radiation."

Torti says that while this study only validates this new type of therapy on breast cancer specifically, it may work on other types of cancer stem cells as well. Many questions about how the heat kills the cells remain, however, and she says it will probably take a good five to 10 years of further study before they can investigate the therapy in human clinical trials.

For now, Torti says that the early success of this approach, detailed in the April 2012 issue of the journal Biomaterials, "gives us a direction to go for a cure." Maybe some day it could serve as a non-invasive alternative to surgically removing certain types of malignant tumors.

Follow this link:
Hot nanotubes blast chemo-resistant cancer cells into oblivion

Posted in Stem Cells | Comments Off on Hot nanotubes blast chemo-resistant cancer cells into oblivion

Heart Disease: Stem Cells To Toothbrushes

Posted: February 16, 2012 at 4:24 am

Related To Story


-Dr.Dianne McCallister, Chief Medical Officer at Centuras Porter Adventist Hospital February is heart month, and we are all familiar with exercise and diet to help our hearts. But do you know how stem cells or your toothbrush can help your heart? This week, Lancet published an article on the use of Stem Cells to help repair the heart.Other medical literature shows a link between the health of your teeth and heart disease. What Are Stem Cells? Stem cells are a type of body cell that still has the ability to become any type of tissue. They work in our bodies to help our tissues repair themselves.When stem cells divide, the new cell has the choice to stay a stem cell - or to become a certain type of tissue cell - in this case, were talking about them become heart muscle cells.For years science has been working on the theory that stem cells could be harvested, grown and then used to repair, or grow organs. Healing Damaged Hearts With Stem Cells The researchers at Cedars-Sinai in Los Angeles took 25 patients who had suffered severe heart attacks - 24% of the muscle in the wall of their ventricle - which is the chamber that pumps blood to the body - was scarred and not functioning.These patients had the normal treatment for heart attacks - but also had stem cells harvested from their heart, grown in the lab, and then re- injected into their hearts.Another group of patients with similar heart attacks just received the usual heart treatment.The patients without stem cells did not show any improvement in their heart muscle - but the stem cell patients had about half the injury to their heart reversed - in other words, the scar was dissolved and replaced with functioning heart muscle.This is a very small study, and it is too early to predict when and if this will become a common treatmentThat being said, it is promising that stem cell therapy may have a new promise for heart attack victims.Standard therapy helps the damaged heart function as well as possible while also limiting the chance of another heart attack.This gives hope that we can reverse the damage.However, we need to remember that there is a lot of testing that needs to happen to determine if there are any unwanted side effects of giving stem cells, when it is appropriate to use them, and what long term effects are from using them. Dental Health And Our Hearts There is growing evidence showing that gum disease has an association with heart disease.We know that gum disease - called gingivitis - allows bacteria from our mouth to get into our blood stream.This is somehow related with inflammation and development of blockages in the vessels of the heart.In addition to brushing, we need to be flossing. Using an antiseptic mouth wash daily and regular dental visits to have teeth cleaned is also important.In fact, good dental health habits are associated with a longer life.There are associations between poor dental health and development of such diseases as diabetes, stroke, lung disease and even pre-term births.So the five minutes you spend twice daily on your teeth is an investment in your overall health as wellDr. McCallister is on 7NEWS at 11 a.m. every Wednesday. If you have a topic or question you would like her to discuss, email 11am@thedenverchannel.com. The following are comments from our users. Opinions expressed are neither created nor endorsed by TheDenverChannel.com. By posting a comment you agree to accept our Terms of Use. Comments are moderated by the community. To report an offensive or otherwise inappropriate comment, click the "Flag" link that appears beneath that comment. Comments that are flagged by a set number of users will be automatically removed.

Read more:
Heart Disease: Stem Cells To Toothbrushes

Posted in Stem Cells | Comments Off on Heart Disease: Stem Cells To Toothbrushes

Promising early results with therapeutic cancer vaccines

Posted: February 16, 2012 at 4:23 am

Public release date: 15-Feb-2012
[ | E-mail | Share ]

Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, February 15, 2012?Therapeutic cancer vaccines, which stimulate the body's immune system to target and destroy cancer cells, are being used in combination with conventional chemotherapy with growing success, as described in several illuminating articles in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com). These articles are available free online at http://www.liebertpub.com/cbr

The U.S. FDA recently approved the first cancer therapeutic vaccine for treatment of metastatic prostate cancer. At least 14 other cancer vaccine strategies are in Phase II or III clinical trials for metastatic melanoma, lung cancer, and lymphoma, for example.

A critical perspective, "Recent Advances in Therapeutic Cancer Vaccines," (http://online.liebertpub.com/doi/full/10.1089/cbr.2012.1200) published in the Journal by Jeffrey Schlom, PhD, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD explains that a key advantage of cancer vaccines used in combination with chemotherapy is the extremely low level of toxicity. "The next frontier for vaccine therapy will be the use of vaccines in combination with certain chemotherapeutic agents, radiation, hormone therapy, and certain small molecule targeted therapies," according to Dr. Schlom.

These emerging areas of cancer vaccine therapy are explored in detail in two accompanying research reports by Dr. Schlom's colleagues at NCI/NIH. James Hodge, Hadley Sharp, and Sofia Gameiro describe how a tumor-targeted vaccine can enhance the effectiveness of radiation therapy on cancer growth and spread beyond the primary tumor in the article "Abscopal Regression of Antigen Disparate Tumors by Antigen Cascade After Systemic Tumor Vaccination in Combination with Local Tumor Radiation." (http://online.liebertpub.com/doi/abs/10.1089/cbr.2012.1202) Drs. Hodge and Gameiro and coauthor Jorge Caballero present the molecular signatures of lung tumor cells that can be made more susceptible to immunotherapy when first exposed to chemotherapeutic agents in the article "Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-cell Killing." (http://online.liebertpub.com/doi/abs/10.1089/cbr.2012.1203)

"This perspective and promising research reports are from one of the leading vaccine research laboratories in the world," says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham. "The ultimate use of cancer vaccines in combination with other immunotherapies, chemotherapy, or radiation therapy will be based on preclinical investigations and hopefully will produce clinical survival benefit for a range of cancers."

###

Cancer Biotherapy and Radiopharmaceuticals, published 10 times a year in print and online, is under the editorial leadership of Editors Donald J. Buchsbaum, PhD and Robert K. Oldham, MD, Lower Keys Cancer Center, Key West, FL. Cancer Biotherapy and Radiopharmaceuticals is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Topics include antibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy, vascular therapy, and inhibitors of proliferation signaling pathways. Complete tables of content and a sample issue may be viewed online at http://www.liebertpub.com/cbr

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Interferon & Cytokine Research; Human Gene Therapy and Human Gene Therapy Methods; and Stem Cells and Development. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at http://www.liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215
http://www.liebertpub.com
Phone: 914-740-2100
800M-LIEBERT
Fax: 914-740-2101


[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Follow this link:
Promising early results with therapeutic cancer vaccines

Posted in Genetic Engineering | Comments Off on Promising early results with therapeutic cancer vaccines

Stem Cell Stocks Skyrocket in 2012 — Cytori Therapeutics and Cord Blood America on the Upswing

Posted: February 16, 2012 at 4:22 am

NEW YORK, NY--(Marketwire -02/15/12)- Stem cell stocks have performed well of late, outperforming the S&P 500 by a large margin over the last three months. Since mid-November, TickerSpy's Stem Cell Stocks index (RXSTM) has returned more than 20 percent, as favorable news from some of stem cell industry heavyweights has boosted investor optimism in the sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cytori Therapeutics, Inc. (NASDAQ: CYTX - News) and Cord Blood America, Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at:

http://www.paragonreport.com/CYTX

http://www.paragonreport.com/CBAI

Shares of Cytori Therapeutics have skyrocketed nearly 70 percent year-to-date. The company develops, manufactures, and sells medical products and devices to enable the practice of regenerative medicine. The Company's technology is the Celuion family of products, which processes patients' adipose-derived stem and regenerative cells (ADRCs) at the point of care.

In late January, Cytori received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the "ATHENA" trial. ATHENA will investigate the use of the Celution System to treat a form of coronary heart disease, chronic myocardial ischemia (CMI).

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http://www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Cord Blood America, Inc. is a holding company that, through its subsidiaries, is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in stem cell therapy.

USA Today recently reported that umbilical cord blood stem cells have been successfully used to treat individuals with type 1 diabetes, highlighting the importance of storing stem cells at birth. The USA Today article says that stem cells from cord blood have been used to "reeducate" the immune system T cells of people with type 1 diabetes so their pancreas started producing insulin again - thereby reducing the amount of insulin they needed to inject.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

See the original post:
Stem Cell Stocks Skyrocket in 2012 -- Cytori Therapeutics and Cord Blood America on the Upswing

Posted in Cell Medicine | Comments Off on Stem Cell Stocks Skyrocket in 2012 — Cytori Therapeutics and Cord Blood America on the Upswing

Bone Repair Stem Cell Breakthrough Shows Promise

Posted: February 16, 2012 at 4:22 am

Editor's Choice
Main Category: Stem Cell Research
Article Date: 15 Feb 2012 - 8:00 PST

email to a friend   printer friendly   opinions  

Current Article Ratings:

Patient / Public:

5 (3 votes)

Healthcare Prof:
According to a study published in the February issue of the STEM CELL Translational Medicine Journal , a world-first technique for generating adult stem cells (mesenchymal stem cells [MSCs]) has been developed by researchers at the University of Queensland. This new method can be used to repair bone and possibly other organs, and will considerably affect individuals suffering from a variety of serious diseases.

Professor Nicholas Fisk, who leads the collaborative study between the UQ Clinical Research Center (UQCCR) and the UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN), explained:

"We used a small molecule to induce embryonic stem cells over a 10 day period, which is much faster than other studies reported in the literature.

The technique also worked on their less contentious counterparts, induced pluripotent stem cells.

To make the pluripotent mature stem cells useful in the clinic, they have to be told what type of cell they need to become (pre-differentiated), before being administered to an injured organ, or otherwise they could form tumors.

Because only small numbers of MSCs exist in the bone marrow, and harvesting bone marrow from a healthy donor is an invasive procedure, the ability to make our own MSCs in large number in the laboratory is an exciting step in the future widespread clinical use of MSCs.

We were able to show these new forms of stem cells exhibited all the characteristics of bone marrow stem cells and we are currently examining their bone repair capability."

Ernst Wolvetang, co-researcher on the study and AIBN Associate Professor, explained that the technique had overcome a considerable obstacle in the translation of stem cell-based therapy.

Wolvetang said: "We are very excited by this research, which has brought together stem cell researchers from two of the major UQ research hubs UQCCR and AIBN."

Written by: Grace Rattue

Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our stem cell research section for the latest news on this subject. UniQuest, The University of Queensland's main commercialization company, invites parties interested in licensing the intellectual property relating to this discovery to contact UniQuest on 3365 4037 or lifesciences@uniquest.com.au.

Source: University of Queensland

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Grace Rattue. "Bone Repair Stem Cell Breakthrough Shows Promise." Medical News Today. MediLexicon, Intl., 15 Feb. 2012. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/articles/241706.php&gt;

APA

Please note: If no author information is provided, the source is cited instead.


Rate this article:
(Hover over the stars then click to rate) Patient / Public:
or Health Professional:

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


See more here:
Bone Repair Stem Cell Breakthrough Shows Promise

Posted in Cell Medicine | Comments Off on Bone Repair Stem Cell Breakthrough Shows Promise

Favorable News From Advanced Cell Technology and StemCells Inc Boosts Optimism in Regenerative Medicine Industry

Posted: February 16, 2012 at 4:22 am

NEW YORK, NY--(Marketwire -02/15/12)- Stem cell stocks have performed well of late, outperforming the S&P 500 by a large margin over the last three months. Since mid-November, TickerSpy's Stem Cell Stocks index (RXSTM) has returned more than 20 percent, as favorable news from some of stem cell industry heavyweights has boosted investor optimism in the sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Advanced Cell Technology, Inc. (OTC.BB: ACTC.OB - News) and StemCells Inc. (NASDAQ: STEM - News). Access to the full company reports can be found at:

http://www.paragonreport.com/ACTC

http://www.paragonreport.com/STEM

Shares of StemCells Inc. have skyrocketed nearly 20 percent year-to-date. StemCells Inc. is focused on cellular medicine, or the use of stem and progenitor cells as the basis for therapeutics and therapies, and enabling technologies for stem cell research, or the use of cells and related technologies to enable stem cell-based research and drug discovery and development.

Earlier this month the company released a statement saying that it received U.S. Food and Drug Administration authorization to start a clinical trial of the company's potential treatment for dry age-related macular degeneration, or AMD. AMD is the leading cause of vision loss and blindness in people over 55 years old and about 30 million people worldwide are affected by the disease, the company said

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http://www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Shares of Advanced Cell Technology are up more than 30 percent this year - although they are down more than 20 percent over the last month. Advanced Cell Technology has acquired, developed and maintained a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research.

Earlier this week Advanced Cell Technology announced that a third patient has been treated for Stargardt's macular dystrophy in its US. Phase I/II clinical trial. The therapy uses retinal pigment epithelial cells derived from human embryonic stem cells. Stargardt's disease or Stargardt's Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

Read the original here:
Favorable News From Advanced Cell Technology and StemCells Inc Boosts Optimism in Regenerative Medicine Industry

Posted in Cell Medicine | Comments Off on Favorable News From Advanced Cell Technology and StemCells Inc Boosts Optimism in Regenerative Medicine Industry

Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for …

Posted: February 16, 2012 at 4:22 am

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the company’s Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD), a form of juvenile macular degeneration, using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. Earlier this year, the Company also announced that the IRB at Wills Eye Institute had approved the participation of the institution as a site for ACT’s clinical trial for dry age-related macular degeneration (dry AMD).

“We thank Wills Eye Institute once more for providing their IRB and their invaluable contribution to our macular degeneration studies,” said Gary Rabin, ACT’s chairman and CEO. “We are very happy that we can now report that Wills Eye Institute has been approved as a clinical trial site for both our SMD and dry AMD clinical trials. Ranked as one of the best ophthalmology hospitals in the country by U.S. News & World Report, the Wills Eye Institute is a truly world-class institution. Our team is eagerly anticipating working with Dr. Carl Regillo, a renowned retinal surgeon and director of clinical retina research at Wills Eye Institute, as well as a professor of ophthalmology at Thomas Jefferson University, along with the rest of his team as we move forward with these ground-breaking trials.”

The Phase I/II trial for SMD is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with SMD. The trial will ultimately enroll 12 patients, with cohorts of three patients each in an ascending dosage format. Preliminary results relating to both early safety and biological function for the first two patients in the U.S., one SMD patient and one dry AMD patient, were recently reported in The Lancet.

Specific patient enrollment for both trials at the Wills Eye Institute will be determined in the near future. Further information about patient eligibility for the SMD study and the concurrent study on dry AMD is also available on http://www.clinicaltrials.gov; ClinicalTrials.gov Identifiers: NCT01345006 and NCT01344993.

About Stargardt's Disease

Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium.

About hESC-derived RPE Cells

The retinal pigment epithelium (RPE) is a highly specialized tissue located between the choroids and the neural retina. RPE cells support, protect and provide nutrition for the light-sensitive photoreceptors. Human embryonic stem cells differentiate into any cell type, including RPE cells, and have a similar expression of RPE-specific genes compared to human RPE cells and demonstrate the full transition from the hESC state.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

About Wills Eye Institute

Wills Eye Institute is a global leader in ophthalmology, established in 1832 as the nation’s first hospital specializing in eye care. U.S. News & World Report has consistently ranked Wills Eye as one of America’s top three ophthalmology centers since the survey began in 1990. Wills Eye is a premier training site for all levels of medical education. Its resident and post-graduate training programs are among the most competitive in the country. One of the core strengths of Wills is the close connection between innovative research and advanced patient care. Wills provides the full range of primary and subspecialty eye care for improving and preserving sight, including cataract, cornea, retina, emergency care, glaucoma, neuro-ophthalmology, ocular oncology, oculoplastics, pathology, pediatric ophthalmology and ocular genetics, refractive surgery and retina. Ocular Services include the Wills Laser Correction Center, Low Vision Service, and Diagnostic Center. Its 24/7 Emergency Service is the only one of its kind in the region. Wills Eye also has a network of nine multi-specialty, ambulatory surgery centers throughout the tri-state area. To learn more, please visit http://www.willseye.org.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.

See the original post:
Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for ...

Posted in Cell Medicine | Comments Off on Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for …

Page 2,862«..1020..2,8612,8622,8632,864..2,8702,880..»